Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




First Saliva Diagnostic Test for Endometriosis Delivers Reliable Results Within Days

By LabMedica International staff writers
Posted on 12 Feb 2025

Endometriosis affects approximately 1 in 10 women globally, with a range of symptoms that can severely impact their health, quality of life, and fertility. More...

The delay in diagnosis, which can take between 7 to 10 years, is a significant barrier to improving care, life quality, and fertility outcomes. Now, a pioneering saliva-based diagnostic test for endometriosis offers new possibilities for early and non-invasive diagnosis of this painful disease.

The Ziwig Endotest, developed by Ziwig (Lyon, France), is a saliva test for endometriosis that provides a reliable diagnosis within just a few days. Ziwig is transforming the diagnosis and treatment of women's health conditions by harnessing the power of salivary RNA. The Ziwig Endotest is the first-ever application of salivary microRNA1-6 in gynecology. This test requires only a simple saliva sample, with the diagnosis performed in the laboratory. It is based on high-throughput sequencing of the microRNA found in saliva, combined with artificial intelligence (AI) to process the large volumes of data generated. Using the Ziwig Endotest, a diagnosis can be made in just a few days with exceptional accuracy (97.4% sensitivity, 93.7% specificity). The test enables clinicians to reliably confirm or exclude a diagnosis of endometriosis and distinguish it from other conditions with similar symptoms. It is particularly useful in complex cases where medical imaging may be inconclusive.

Ziwig’s non-invasive approach to saliva sampling, along with technological advancements in sequencing and AI, makes accurate, early diagnosis of endometriosis more accessible. The company’s focus on the RNA and extracellular vesicles in saliva represents a milestone in personalized medicine. The Ziwig Endotest offers a breakthrough biological test for healthcare providers and patients by reducing diagnostic delays, identifying complex and early-stage cases sooner, providing an alternative to invasive procedures, and enhancing fertility preservation through earlier diagnosis.

"With Ziwig Endotest we are determined to end the unacceptable diagnostic wandering that leaves many women in pain,” said Yahya El Mir, Ziwig CEO-Founder.

Related Links:
Ziwig


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Ultra-Low Temperature Freezer
iUF118-GX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.